midodrine has been researched along with Endotoxin Shock in 10 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effective oral dosage in infancy and childhood is 0." | 6.65 | [Infectious toxic hypotension--effect and dosage of midodrine (author's transl)]. ( Weippl, G, 1979) |
| "The use of midodrine in septic shock patients significantly reduced IV norepinephrine duration, weaning period during the septic shock recovery phase, and mortality." | 3.11 | Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial. ( Adly, DHE; Anan, IF; Bazan, NS; El Borolossy, RM; El Wakeel, LM; Fakher, MA, 2022) |
| "Adding midodrine to patients with septic shock was associated with a reduction in hospital mortality [risk ratio (RR) 0." | 3.01 | Effect of midodrine on the prognosis of patients with septic shock: a systematic review and meta-analysis. ( He, QF; Jiang, ZX; Wang, TQ; Xing, XK; Zhang, G, 2023) |
| "Midodrine is an orally administered alpha-1 adrenergic agonist while methylene blue is an intravenously administered blue dye used to restore vascular tone and increase blood pressure." | 2.66 | Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. ( Sullivan, JB; Tchen, S, 2020) |
| " The effective oral dosage in infancy and childhood is 0." | 2.65 | [Infectious toxic hypotension--effect and dosage of midodrine (author's transl)]. ( Weippl, G, 1979) |
| "All study subjects had a diagnosis of septic shock requiring at least 24 hours of IV vasopressors and demonstrated clinical stability with stable or decreasing doses of IV vasopressors." | 1.43 | Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. ( Healy, L; Koenig, S; Mayo, PH; Mo, E; Nabi, T; Narasimhan, M; Whitson, MR, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adly, DHE | 1 |
| Bazan, NS | 1 |
| El Borolossy, RM | 1 |
| Anan, IF | 1 |
| Fakher, MA | 1 |
| El Wakeel, LM | 1 |
| He, QF | 1 |
| Xing, XK | 1 |
| Wang, TQ | 1 |
| Jiang, ZX | 1 |
| Zhang, G | 1 |
| Gupta, S | 1 |
| Sen, A | 1 |
| Verma, A | 1 |
| Tchen, S | 1 |
| Sullivan, JB | 1 |
| Davoudi-Monfared, E | 1 |
| Mohammadi, M | 1 |
| Khoshavi, M | 1 |
| Khalili, H | 1 |
| Whitson, MR | 1 |
| Mo, E | 1 |
| Nabi, T | 1 |
| Healy, L | 1 |
| Koenig, S | 1 |
| Narasimhan, M | 1 |
| Mayo, PH | 1 |
| Hammond, DA | 1 |
| Smith, MN | 1 |
| Meena, N | 1 |
| Sagar, AS | 1 |
| Vijhani, P | 1 |
| Walter, JM | 1 |
| Kruser, JM | 1 |
| Reyfman, PA | 1 |
| Sporn, PH | 1 |
| Weippl, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RANDOMIZED CASE-CONTROLLED TRIAL ASSESSING MIDODRINE (GUTRON®) IN POSTOPERATIVE VASOPLEGIC PATIENTS[NCT04440085] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-09-14 | Not yet recruiting | ||
| Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients[NCT03911817] | Phase 4 | 60 participants (Actual) | Interventional | 2017-11-15 | Completed | ||
| A Randomized Controlled Trial of Midodrine During Recovery Phase From Septic Shock[NCT02771158] | Phase 4 | 0 participants (Actual) | Interventional | 2017-08-31 | Withdrawn (stopped due to Study never started) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for midodrine and Endotoxin Shock
| Article | Year |
|---|---|
Effect of midodrine on the prognosis of patients with septic shock: a systematic review and meta-analysis.
Topics: Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Midodrine; Prognosis; Shock, Septi | 2023 |
Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock.
Topics: Blood Pressure; Catecholamines; Critical Care; Critical Illness; Humans; Hypotension; Intensive Care | 2020 |
3 trials available for midodrine and Endotoxin Shock
| Article | Year |
|---|---|
Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial.
Topics: Humans; Midodrine; Norepinephrine; Prospective Studies; Shock, Septic; Vasoconstrictor Agents | 2022 |
The effect of midodrine on lactate clearance in patients with septic shock: a pilot study.
Topics: Humans; Lactic Acid; Midodrine; Pilot Projects; Shock, Septic; Vasoconstrictor Agents | 2021 |
[Infectious toxic hypotension--effect and dosage of midodrine (author's transl)].
Topics: Bacterial Infections; Blood Pressure; Child; Child, Preschool; Clinical Trials as Topic; Drug Evalua | 1979 |
5 other studies available for midodrine and Endotoxin Shock
| Article | Year |
|---|---|
Should midodrine be used as an intravenous vasopressor-sparing agent in septic shock?
Topics: Administration, Intravenous; Humans; Midodrine; Retrospective Studies; Shock, Septic; Vasoconstricto | 2023 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Topics: Aged; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Intensiv | 2016 |
Considerations on Midodrine Use in Resolving Septic Shock.
Topics: Blood Pressure; Humans; Midodrine; Sepsis; Shock, Septic | 2016 |
Using the Proper Analytical Tools When Evaluating the Role of Midodrine in Resolving Septic Shock.
Topics: Humans; Midodrine; Shock, Septic; Vasoconstrictor Agents | 2016 |
Postextubation High-Flow Nasal Cannula Oxygen, Randomized Trial of an ICU Quality Improvement Intervention, and Midodrine during Recovery from Septic Shock.
Topics: Cannula; Humans; Intensive Care Units; Midodrine; Oxygen; Oxygen Inhalation Therapy; Quality Improve | 2017 |